Pet Osteoarthritis Treatment Market
PUBLISHED: 2026 ID: SMRC40472
SHARE
SHARE

Pet Osteoarthritis Treatment Market

Pet Osteoarthritis Treatment Market Forecasts to 2034 - Global Analysis By Treatment Type (Pharmaceuticals, Biologics and Regenerative Therapies, Nutraceuticals and Joint Supplements, Rehabilitation and Physical Therapy), Drug Class, Pet Type, Distribution Channel, and By Geography

4.7 (84 reviews)
4.7 (84 reviews)
Published: 2026 ID: SMRC40472

Due to ongoing shifts in global trade and tariffs, the market outlook will be refreshed before delivery, including updated forecasts and quantified impact analysis. Recommendations and Conclusions will also be revised to offer strategic guidance for navigating the evolving international landscape.
Loading...
According to Stratistics MRC, the Global Pet Osteoarthritis Treatment Market is accounted for $3.3 billion in 2026 and is expected to reach $6.1 billion by 2034 growing at a CAGR of 8% during the forecast period. Pet osteoarthritis treatment encompasses pharmaceutical, biological, nutritional, and rehabilitative interventions designed to manage joint pain, inflammation, mobility limitations, and functional decline in companion animals. The market includes pharmaceuticals, biologics and regenerative therapies, nutraceuticals and joint supplements, and rehabilitation and physical therapy. Treatment options include nonsteroidal anti-inflammatory drugs (NSAIDs), analgesics, anti-nerve growth factor therapies, and other pain-management drugs, primarily serving dogs and cats through veterinary hospitals and clinics, veterinary pharmacies, and online pharmacies. Increasing pet longevity, growing awareness of animal pain management, and advances in veterinary therapeutics are supporting market development.

Market Dynamics:

Driver:

Increasing prevalence of osteoarthritis in aging companion animals

The growing population of aging companion animals is a major driver of the pet osteoarthritis treatment market. Osteoarthritis is a chronic degenerative joint condition that can cause persistent pain, stiffness, reduced mobility, and difficulty performing everyday activities. As dogs and cats live longer, demand for veterinary assessment and long-term pain management is increasing. Greater awareness among pet owners of mobility changes and age-related joint disorders is encouraging earlier veterinary consultations. Advances in pharmaceutical treatments, including targeted biological therapies and established anti-inflammatory medications, are expanding the available treatment options. Additionally, increasing expenditure on companion animal healthcare is supporting demand for prescription medications, joint supplements, and supportive rehabilitation services.

Restraint:

High treatment costs and limitations associated with long-term medication use

The cost of managing pet osteoarthritis can constrain treatment uptake, particularly when animals require ongoing medication, veterinary consultations, diagnostic examinations, and rehabilitation. Biological therapies and newer targeted treatments may involve higher costs than conventional medications, potentially limiting access among price-sensitive pet owners. Long-term pharmaceutical management also requires appropriate veterinary supervision because treatment suitability, contraindications, and adverse effects vary across animals. NSAIDs may require monitoring of gastrointestinal, kidney, and liver health, while other therapies have their own safety considerations. In addition, owners may delay treatment when early symptoms are subtle or difficult to distinguish from normal age-related changes, potentially increasing the complexity of subsequent care.

Opportunity:

Advancements in biological therapies and multimodal osteoarthritis management

Advances in targeted veterinary medicines and multimodal treatment approaches are creating opportunities for market participants. Anti-NGF monoclonal antibody therapies provide an alternative mechanism for managing osteoarthritis-associated pain, while pharmaceutical treatments, nutritional supplements, weight management, and physical rehabilitation can contribute to individualized care plans. The introduction of longer-acting therapies may also reduce the frequency of treatment administration and improve convenience for eligible patients. Additionally, research into regenerative medicine, including cell-based approaches and other biological interventions, is expanding the range of potential treatment options. Growing investment in veterinary clinical research, diagnostic capabilities, and professional education can further support innovation and adoption across companion animal healthcare markets.

Threat:

Regulatory scrutiny and competition among treatment alternatives

The pet osteoarthritis treatment market faces challenges from regulatory requirements, product safety monitoring, and competition among pharmaceutical and non-pharmaceutical interventions. Veterinary medicines must demonstrate appropriate safety, efficacy, and quality for their intended indications, while post-marketing surveillance can lead to labeling updates and changes in prescribing practices. Established NSAIDs compete with newer targeted therapies, supplements, rehabilitation services, and other supportive approaches. Differences in treatment response among individual animals can also influence veterinary and owner preferences. Furthermore, product development and clinical evaluation require substantial investment, while patent protection, commercialization costs, and market access requirements can affect competitive positioning. Manufacturers must maintain confidence through transparent safety communication and continued clinical evidence generation.

Covid-19 Impact:

The COVID-19 pandemic affected veterinary healthcare through temporary clinic restrictions, changes in appointment availability, supply chain disruptions, and shifts in household spending. Some routine veterinary consultations and elective assessments were postponed, potentially delaying the diagnosis and management of chronic conditions such as osteoarthritis. At the same time, increased time spent at home heightened some pet owners' awareness of companion animal health and mobility. Veterinary practices increasingly adopted digital communication and appointment management tools, while online purchasing gained importance for certain pet healthcare products. Following the pandemic, the continued focus on preventive veterinary care, pet longevity, and quality of life has supported demand for chronic pain management, prescription therapies, and supportive treatment services.

The Pharmaceuticals segment is expected to be the largest during the forecast period

The Pharmaceuticals segment is expected to account for the largest market share during the forecast period, supported by the established use of prescription medications to manage osteoarthritis-associated pain and inflammation in companion animals. NSAIDs and other analgesics remain important treatment options for eligible dogs and cats, with veterinary professionals selecting therapies according to the animal's condition, medical history, and treatment response. The availability of established brands and newer targeted medicines supports pharmaceutical demand across veterinary hospitals and clinics. In addition, chronic disease management often requires ongoing treatment and follow-up consultations, contributing to recurring demand for veterinary medications. Continued innovation in pain-management therapies is further strengthening the pharmaceutical treatment landscape.

The Biologics and Regenerative Therapies segment is expected to witness strong growth during the forecast period

The Biologics and Regenerative Therapies segment is expected to experience strong growth as veterinary medicine advances toward targeted approaches for managing chronic joint pain. Anti-NGF monoclonal antibody therapies have expanded treatment options for canine and feline osteoarthritis, offering a mechanism distinct from conventional NSAIDs. Longer-acting biological products may improve convenience by reducing administration frequency, while continued research into regenerative medicine is generating interest in approaches intended to support joint function and tissue health. Growing awareness of chronic pain management, increasing demand for individualized treatment, and continued investment in veterinary therapeutics are supporting segment development.

The Anti-Nerve Growth Factor Therapies segment is expected to witness strong growth during the forecast period

The Anti-Nerve Growth Factor Therapies segment is expected to record strong growth as veterinary medicine increasingly adopts targeted biological treatments for osteoarthritis-associated pain. These therapies act on nerve growth factor, a protein involved in pain signaling, and provide an alternative to conventional anti-inflammatory medication for eligible companion animals. Products such as Librela for dogs and Solensia for cats have established anti-NGF treatment options in major veterinary markets. The introduction of additional long-acting therapies, including newer products designed to provide pain relief for longer intervals, is broadening the treatment landscape. Greater veterinary familiarity with targeted therapeutics and increasing attention to chronic pain management are expected to support segment expansion.

Region with largest share:

During the forecast period, North America is expected to hold the largest market share, supported by established veterinary healthcare infrastructure, substantial companion animal healthcare expenditure, and broad availability of prescription treatments. The United States represents a major market for veterinary pharmaceuticals and biological therapies, supported by established animal health companies, specialist veterinary practices, and product distribution networks. Regulatory approvals and commercial availability of established osteoarthritis medicines contribute to treatment accessibility. Furthermore, increasing attention to senior pet care, routine veterinary examinations, and chronic disease management supports demand for pharmaceutical interventions, joint supplements, and rehabilitation services. These factors reinforce North America's leading position in the pet osteoarthritis treatment market.

Region with highest CAGR:

The Asia Pacific region is expected to witness the highest CAGR during the forecast period, driven by increasing companion animal ownership, expanding veterinary service networks, rising disposable incomes, and growing awareness of animal health. Urbanization and changing household lifestyles are supporting expenditure on veterinary consultations, prescription medicines, and preventive healthcare. China, Japan, Australia, South Korea, and India offer opportunities for pharmaceutical manufacturers and veterinary service providers as access to specialized pet healthcare expands. Increasing availability of online veterinary pharmacies and growing professional awareness of chronic joint disorders are also supporting market development. These trends are expected to accelerate adoption of pet osteoarthritis treatments across the region.

Key players in the market

Some of the key players in the Global Pet Osteoarthritis Treatment Market include Zoetis Inc., Boehringer Ingelheim, Elanco Animal Health Incorporated, Dechra Pharmaceuticals PLC, Virbac, Vetoquinol S.A., Kindred Biosciences, American Regent Animal Health, Nutramax Laboratories Veterinary Sciences, Inc., and Assisi Animal Health.

Key Developments:

In October 2026, Boehringer Ingelheim announced the availability of its new Quarterable Snap-Tab design for PREVICOX (firocoxib) chewable tablets in the United States following FDA approval. The updated design enables tablets to be divided into quarters, providing more flexible dosing options based on dogs' body weight and improving convenience for veterinary professionals and pet owners.

In September 2026, Zoetis launched Lenivia (izenivetmab injection) in Great Britain. The long-acting monoclonal antibody therapy is designed to alleviate osteoarthritis-associated pain in dogs for up to three months following a single injection, expanding treatment options for canine chronic pain management.

In July 2026, Zoetis launched Lenivia in Canada and European Union member states. The commercial expansion increased the availability of its long-acting canine osteoarthritis treatment across additional veterinary markets and strengthened the company's targeted pain-management portfolio.

In July 2026, Zoetis launched Portela (relfovetmab) in Canada and the European Union. The long-acting anti-NGF monoclonal antibody therapy for cats is designed to provide osteoarthritis-associated pain relief for up to three months following a single subcutaneous injection, expanding biological treatment options for feline osteoarthritis.

Treatment Types Covered:
• Pharmaceuticals
• Biologics and Regenerative Therapies
• Nutraceuticals and Joint Supplements
• Rehabilitation and Physical Therapy

Drug Classes Covered:
• NSAIDs and Analgesics
• Anti-Nerve Growth Factor Therapies
• Other Pain-Management Drugs

Pet Types Covered:
• Dogs
• Cats

Distribution Channels Covered:
• Veterinary Hospitals and Clinics
• Veterinary Pharmacies
• Online Pharmacies

Regions Covered:
• North America
o United States
o Canada
o Mexico
• Europe
o United Kingdom
o Germany
o France
o Italy
o Spain
o Netherlands
o Belgium
o Sweden
o Switzerland
o Poland
o Rest of Europe
• Asia Pacific
o China
o Japan
o India
o South Korea
o Australia
o Indonesia
o Thailand
o Malaysia
o Singapore
o Vietnam
o Rest of Asia Pacific
• South America
o Brazil
o Argentina
o Colombia
o Chile
o Peru
o Rest of South America
• Rest of the World (RoW)
o Middle East
§ Saudi Arabia
§ United Arab Emirates
§ Qatar
§ Israel
§ Rest of Middle East
o Africa
§ South Africa
§ Egypt
§ Morocco
§ Rest of Africa

What our report offers:
• Market share assessments for regional and country-level segments
• Strategic recommendations for new entrants
• Covers market data for the years 2023, 2024, 2025, 2026, 2027, 2028, 2030, 2032, and 2034
• Market trends, including drivers, constraints, opportunities, threats, challenges, investment opportunities, and recommendations
• Strategic recommendations for key business segments based on market estimations
• Competitive landscape mapping and assessment of key industry trends
• Company profiling with detailed strategies, financials, and recent developments
• Supply chain trends and assessment of the latest technological advancements

Free Customization Offerings:
All customers of this report will be entitled to receive one of the following free customization options:
• Company Profiling
o Comprehensive profiling of additional market players (up to 3)
o SWOT analysis of key players (up to 3)
• Regional Segmentation
o Market estimations, forecasts, and CAGR of any prominent country as per the client's interest (subject to feasibility assessment)
• Competitive Benchmarking
o Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary
1.1 Market Snapshot and Key Highlights
1.2 Growth Drivers, Challenges, and Opportunities
1.3 Competitive Landscape Overview
1.4 Strategic Insights and Recommendations

2 Research Framework
2.1 Study Objectives and Scope
2.2 Stakeholder Analysis
2.3 Research Assumptions and Limitations
2.4 Research Methodology
2.4.1 Data Collection (Primary and Secondary)
2.4.2 Data Modeling and Estimation Techniques
2.4.3 Data Validation and Triangulation
2.4.4 Analytical and Forecasting Approach

3 Market Dynamics and Trend Analysis
3.1 Market Definition and Structure
3.2 Key Market Drivers
3.3 Market Restraints and Challenges
3.4 Growth Opportunities and Investment Hotspots
3.5 Industry Threats and Risk Assessment
3.6 Technology and Innovation Landscape
3.7 Emerging and High-Growth Markets
3.8 Regulatory and Policy Environment
3.9 Impact of COVID-19 and Recovery Outlook

4 Competitive and Strategic Assessment
4.1 Porter's Five Forces Analysis
4.1.1 Supplier Bargaining Power
4.1.2 Buyer Bargaining Power
4.1.3 Threat of Substitutes
4.1.4 Threat of New Entrants
4.1.5 Competitive Rivalry
4.2 Market Share Analysis of Key Players
4.3 Product Benchmarking and Performance Comparison

5 Global Pet Osteoarthritis Treatment Market, By Treatment Type
5.1 Pharmaceuticals
5.2 Biologics and Regenerative Therapies
5.3 Nutraceuticals and Joint Supplements
5.4 Rehabilitation and Physical Therapy

6 Global Pet Osteoarthritis Treatment Market, By Drug Class
6.1 NSAIDs and Analgesics
6.2 Anti-Nerve Growth Factor Therapies
6.3 Other Pain-Management Drugs

7 Global Pet Osteoarthritis Treatment Market, By Pet Type
7.1 Dogs
7.2 Cats

8 Global Pet Osteoarthritis Treatment Market, By Distribution Channel
8.1 Veterinary Hospitals and Clinics
8.2 Veterinary Pharmacies
8.3 Online Pharmacies

9 Global Pet Osteoarthritis Treatment Market, By Geography
9.1 North America
9.1.1 United States
9.1.2 Canada
9.1.3 Mexico
9.2 Europe
9.2.1 United Kingdom
9.2.2 Germany
9.2.3 France
9.2.4 Italy
9.2.5 Spain
9.2.6 Netherlands
9.2.7 Belgium
9.2.8 Sweden
9.2.9 Switzerland
9.2.10 Poland
9.2.11 Rest of Europe
9.3 Asia Pacific
9.3.1 China
9.3.2 Japan
9.3.3 India
9.3.4 South Korea
9.3.5 Australia
9.3.6 Indonesia
9.3.7 Thailand
9.3.8 Malaysia
9.3.9 Singapore
9.3.10 Vietnam
9.3.11 Rest of Asia Pacific
9.4 South America
9.4.1 Brazil
9.4.2 Argentina
9.4.3 Colombia
9.4.4 Chile
9.4.5 Peru
9.4.6 Rest of South America
9.5 Rest of the World (RoW)
9.5.1 Middle East
9.5.1.1 Saudi Arabia
9.5.1.2 United Arab Emirates
9.5.1.3 Qatar
9.5.1.4 Israel
9.5.1.5 Rest of Middle East
9.5.2 Africa
9.5.2.1 South Africa
9.5.2.2 Egypt
9.5.2.3 Morocco
9.5.2.4 Rest of Africa

10 Strategic Market Intelligence
10.1 Industry Value Network and Supply Chain Assessment
10.2 White-Space and Opportunity Mapping
10.3 Product Evolution and Market Life Cycle Analysis
10.4 Channel, Distributor, and Go-to-Market Assessment

11 Industry Developments and Strategic Initiatives
11.1 Mergers and Acquisitions
11.2 Partnerships, Alliances, and Joint Ventures
11.3 New Product Launches and Certifications
11.4 Capacity Expansion and Investments
11.5 Other Strategic Initiatives

12 Company Profiles
12.1 Zoetis Inc.
12.2 Boehringer Ingelheim
12.3 Elanco Animal Health Incorporated
12.4 Dechra Pharmaceuticals PLC
12.5 Virbac
12.6 Vetoquinol S.A.
12.7 Kindred Biosciences (as applicable to legacy products)
12.8 American Regent Animal Health
12.9 Nutramax Laboratories Veterinary Sciences, Inc.
12.10 Assisi Animal Health

List of Tables
1 Global Pet Osteoarthritis Treatment Market Outlook, By Region (2023–2034) ($MN)
2 Global Pet Osteoarthritis Treatment Market Outlook, By Treatment Type (2023–2034) ($MN)
3 Global Pet Osteoarthritis Treatment Market Outlook, By Pharmaceuticals (2023–2034) ($MN)
4 Global Pet Osteoarthritis Treatment Market Outlook, By Biologics and Regenerative Therapies (2023–2034) ($MN)
5 Global Pet Osteoarthritis Treatment Market Outlook, By Nutraceuticals and Joint Supplements (2023–2034) ($MN)
6 Global Pet Osteoarthritis Treatment Market Outlook, By Rehabilitation and Physical Therapy (2023–2034) ($MN)
7 Global Pet Osteoarthritis Treatment Market Outlook, By Drug Class (2023–2034) ($MN)
8 Global Pet Osteoarthritis Treatment Market Outlook, By NSAIDs and Analgesics (2023–2034) ($MN)
9 Global Pet Osteoarthritis Treatment Market Outlook, By Anti-Nerve Growth Factor Therapies (2023–2034) ($MN)
10 Global Pet Osteoarthritis Treatment Market Outlook, By Other Pain-Management Drugs (2023–2034) ($MN)
11 Global Pet Osteoarthritis Treatment Market Outlook, By Pet Type (2023–2034) ($MN)
12 Global Pet Osteoarthritis Treatment Market Outlook, By Dogs (2023–2034) ($MN)
13 Global Pet Osteoarthritis Treatment Market Outlook, By Cats (2023–2034) ($MN)
14 Global Pet Osteoarthritis Treatment Market Outlook, By Distribution Channel (2023–2034) ($MN)
15 Global Pet Osteoarthritis Treatment Market Outlook, By Veterinary Hospitals and Clinics (2023–2034) ($MN)
16 Global Pet Osteoarthritis Treatment Market Outlook, By Veterinary Pharmacies (2023–2034) ($MN)
17 Global Pet Osteoarthritis Treatment Market Outlook, By Online Pharmacies (2023–2034) ($MN)

Note: Tables for North America, Europe, APAC, South America, and Rest of the World (RoW) Regions are also represented in the same manner as above.

List of Figures

RESEARCH METHODOLOGY


Research Methodology

We at ‘Stratistics’ opt for an extensive research approach which involves data mining, data validation, and data analysis. The various research sources include in-house repository, secondary research, competitor’s sources, social media research, client internal data, and primary research.

Our team of analysts prefers the most reliable and authenticated data sources in order to perform the comprehensive literature search. With access to most of the authenticated data bases our team highly considers the best mix of information through various sources to obtain extensive and accurate analysis.

Each report takes an average time of a month and a team of 4 industry analysts. The time may vary depending on the scope and data availability of the desired market report. The various parameters used in the market assessment are standardized in order to enhance the data accuracy.

Data Mining

The data is collected from several authenticated, reliable, paid and unpaid sources and is filtered depending on the scope & objective of the research. Our reports repository acts as an added advantage in this procedure. Data gathering from the raw material suppliers, distributors and the manufacturers is performed on a regular basis, this helps in the comprehensive understanding of the products value chain. Apart from the above mentioned sources the data is also collected from the industry consultants to ensure the objective of the study is in the right direction.

Market trends such as technological advancements, regulatory affairs, market dynamics (Drivers, Restraints, Opportunities and Challenges) are obtained from scientific journals, market related national & international associations and organizations.

Data Analysis

From the data that is collected depending on the scope & objective of the research the data is subjected for the analysis. The critical steps that we follow for the data analysis include:

  • Product Lifecycle Analysis
  • Competitor analysis
  • Risk analysis
  • Porters Analysis
  • PESTEL Analysis
  • SWOT Analysis

The data engineering is performed by the core industry experts considering both the Marketing Mix Modeling and the Demand Forecasting. The marketing mix modeling makes use of multiple-regression techniques to predict the optimal mix of marketing variables. Regression factor is based on a number of variables and how they relate to an outcome such as sales or profits.


Data Validation

The data validation is performed by the exhaustive primary research from the expert interviews. This includes telephonic interviews, focus groups, face to face interviews, and questionnaires to validate our research from all aspects. The industry experts we approach come from the leading firms, involved in the supply chain ranging from the suppliers, distributors to the manufacturers and consumers so as to ensure an unbiased analysis.

We are in touch with more than 15,000 industry experts with the right mix of consultants, CEO's, presidents, vice presidents, managers, experts from both supply side and demand side, executives and so on.

The data validation involves the primary research from the industry experts belonging to:

  • Leading Companies
  • Suppliers & Distributors
  • Manufacturers
  • Consumers
  • Industry/Strategic Consultants

Apart from the data validation the primary research also helps in performing the fill gap research, i.e. providing solutions for the unmet needs of the research which helps in enhancing the reports quality.


For more details about research methodology, kindly write to us at info@strategymrc.com

Frequently Asked Questions

In case of any queries regarding this report, you can contact the customer service by filing the “Inquiry Before Buy” form available on the right hand side. You may also contact us through email: info@strategymrc.com or phone: +1-301-202-5929

Yes, the samples are available for all the published reports. You can request them by filling the “Request Sample” option available in this page.

Yes, you can request a sample with your specific requirements. All the customized samples will be provided as per the requirement with the real data masked.

All our reports are available in Digital PDF format. In case if you require them in any other formats, such as PPT, Excel etc you can submit a request through “Inquiry Before Buy” form available on the right hand side. You may also contact us through email: info@strategymrc.com or phone: +1-301-202-5929

We offer a free 15% customization with every purchase. This requirement can be fulfilled for both pre and post sale. You may send your customization requirements through email at info@strategymrc.com or call us on +1-301-202-5929.

We have 3 different licensing options available in electronic format.

  • Single User Licence: Allows one person, typically the buyer, to have access to the ordered product. The ordered product cannot be distributed to anyone else.
  • 2-5 User Licence: Allows the ordered product to be shared among a maximum of 5 people within your organisation.
  • Corporate License: Allows the product to be shared among all employees of your organisation regardless of their geographical location.

All our reports are typically be emailed to you as an attachment.

To order any available report you need to register on our website. The payment can be made either through CCAvenue or PayPal payments gateways which accept all international cards.

We extend our support to 6 months post sale. A post sale customization is also provided to cover your unmet needs in the report.

Request Customization

We offer complimentary customization of up to 15% with every purchase.

To share your customization requirements, feel free to email us at info@strategymrc.com or call us on +1-301-202-5929. .

Please Note: Customization within the 15% threshold is entirely free of charge. If your request exceeds this limit, we will conduct a feasibility assessment. Following that, a detailed quote and timeline will be provided.

WHY CHOOSE US ?

Assured Quality

Assured Quality

Best in class reports with high standard of research integrity

24X7 Research Support

24X7 Research Support

Continuous support to ensure the best customer experience.

Free Customization

Free Customization

Adding more values to your product of interest.

Safe and Secure Access

Safe & Secure Access

Providing a secured environment for all online transactions.

Trusted by 600+ Brands

Trusted by 600+ Brands

Serving the most reputed brands across the world.

Testimonials